CDC WONDER (ICPSR 128)
The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] (ICPSR 36575)
The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] study (CVAR) was a research study of why large United States Metropolitan Statistical Areas (MSAs) vary over time in their vulnerability to HIV/AIDS among drug users and in MSA responses to HIV/AIDS. This collection contains estimates of HIV prevalence among people who injected drugs (PWID) and among sub-populations of PWID. This collection is comprised of ten datasets with differing amounts of variables and provides trend data that describe the following:
- Epidemiologic outcomes including population prevalence of PWIDs and Non-injecting drug users (NIDUs), and particularly their prevalence among youth; and, among PWIDs, HIV prevalence, late-diagnosis HIV cases, and AIDS incidence and mortality.
- Implementation of evidence-based drug-related interventions including drug abuse treatment, syringe exchange, HIV counseling and testing.
- Implementation of non-evidence-based drug-related interventions including incarceration and arrests of drug users.
The collection contains data on the MSA sub-populations including Black, Hispanic, White and "other" race categories. In addition, some statistics are presented in age range categories such as ages 15-29, 30-64 and 15-64.
Midlife in the United States: Core Sample Mortality Data, 1995-2023 (ICPSR 37237)
In 1995-1996, the MacArthur Midlife Research Network carried out a national survey of over 7,000 Americans aged 25 to 74 (ICPSR 2760). The purpose of the study was to investigate the role of behavioral, psychological, and social factors in understanding age-related differences in physical and mental health.
With support from the National Institute on Aging, an initial follow-up of the original Midlife Development in the United States (MIDUS) samples was conducted in 2004 (MIDUS 2). The daily stress and cognitive functioning projects were repeated at MIDUS 2; in addition the protocol was expanded to include biomarkers and neuroscience. In 2005, a baseline sample of 592 African Americans from Milwaukee was added to MIDUS to examine health issues in minority populations.
In 2013, a third wave (MIDUS 3) of survey data was collected on longitudinal participants. Data collection for this follow-up wave largely repeated baseline assessments (e.g., phone interview and extensive self-administered questionnaire), with additional questions in selected areas (e.g., economic recession experiences, optimism and coping, stressful life events, and caregiving). A third wave of cognitive functioning data and a second wave of the Milwaukee sample were also collected. Data collection for the daily diary, biomarkers, and neuroscience is ongoing. This dataset includes all known MIDUS decedents (N=2,533) from the Core National and Milwaukee samples as of December 2023.
Monitoring the Future Longitudinal Panel Mortality Data, 1976-2021 [Restricted-Use] (ICPSR 39651)
Since 1976, Monitoring the Future (MTF) has enrolled ~2,450 individuals each year from its nationally representative annual sample of 12th graders into the MTF Longitudinal Panel study. A primary goal of the MTF study is to examine potential consequences of substance use across the life course, including mortality. Therefore, the MTF Longitudinal Panel study now includes measures of mortality linked to the National Death Index (NDI).
The MTF Longitudinal Panel Study Mortality Data 1976-2021 file includes MTF Longitudinal Panel members from the high school cohorts of 1976-2021 whose mortality status was confirmed through either (a) the MTF NDI match process (limited to high school cohorts 1976-2019) or (b) the MTF panel tracking process (including 1976-2021 cohorts, tracking through August 2025).